Cancer Therapy: A Role for MAPK Inhibitors Combined with mTORC1 Inhibitors
Beth Israel Lahey HealthResearchers led by scientists at Beth Israel Deaconess Medical Center identify a previously unrecognized problem faced by mTOR inhibitors, shining a light on the MAPK pathway.